News
ATHE
4.720
+3.85%
0.175
Alterity Therapeutics Price Target Announced at $12.00/Share by Craig-Hallum
Dow Jones · 4h ago
Craig-Hallum Initiates Coverage On Alterity Therapeutics with Buy Rating, Announces Price Target of $12
Benzinga · 4h ago
Craig-Hallum bullish on Alterity Therapeutics, initiates with a Buy
TipRanks · 8h ago
Alterity Therapeutics initiated with a Buy at Craig-Hallum
TipRanks · 9h ago
Weekly Report: what happened at ATHE last week (0803-0807)?
Weekly Report · 1d ago
Alterity Therapeutics Files August 3 Application to Quote ATH Securities
TipRanks · 08/04 10:28
Weekly Report: what happened at ATHE last week (0727-0731)?
Weekly Report · 08/03 09:04
Alterity Therapeutics Secures FDA Pathway and Bolsters Funding for ATH434 Phase 3 in MSA
TipRanks · 07/30 10:37
Alterity Therapeutics Releases Appendix 4C – Q4 FY26 Quarterly Cash Flow Report & Corporate Update
Barchart · 07/30 06:25
Weekly Report: what happened at ATHE last week (0720-0724)?
Weekly Report · 07/27 09:04
Catalyst Watch: Tech majors report, FOMC, Jersey Mike's IPO and more oil anxiety
Seeking Alpha · 07/24 19:00
Alterity Therapeutics Files Form 6-K and Seeks Quotation for ATH Securities
TipRanks · 07/21 10:32
Alterity Therapeutics CEO to Engage U.S. Investors at BTIG Biotechnology Conference 2026
TipRanks · 07/21 10:31
Alterity Therapeutics to Participate in the Virtual BTIG Biotechnology Conference 2026
Barchart · 07/21 06:25
Weekly Report: what happened at ATHE last week (0713-0717)?
Weekly Report · 07/20 09:04
Weekly Report: what happened at ATHE last week (0706-0710)?
Weekly Report · 07/13 09:04
Analysts Are Bullish on These Healthcare Stocks: Alterity Therapeutics (ATHE), Vera Therapeutics (VERA)
TipRanks · 07/08 13:10
Alterity To Initiate Phase 3 Trial Of ATH434 In MSA Subsequent To Receipt Of EOP2 Minutes From FDA
NASDAQ · 07/07 15:02
Alterity Therapeutics receives FDA meeting minutes on pathway for ATH434
TipRanks · 07/07 11:35
Alterity Therapeutics Receives Official Meeting Minutes From Fda End-of Phase-2 Meeting For ATH434 In Multiple System Atrophy; Pivotal Phase 3 Trial Activities On Track To Initiate By End Of 2026
Benzinga · 07/07 11:11
More
Webull provides a variety of real-time ATHE stock news. You can receive the latest news about Alterity Therapeutics Ltd through multiple platforms. This information may help you make smarter investment decisions.
About ATHE
Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. Its lead asset, ATH434, is in a randomized, double blind, placebo-controlled Phase II clinical trial in participants with MSA. The Company is also conducting various nonclinical studies with ATH434 for use in Parkinson’s disease based on imaging of brain iron, preservation of neurons, and improvements in motor performance.